Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED EP-NEC SELECTED AS LBA AND THREE STUDIES SELECTED FOR PROFFERED PAPER PRESENTATIONS AT 2026 ESMO

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that the pivotal registrational Phase IIb clinical study of its self-developed drug candidate LBL-024 (Opamtistomig, PD-L1/4-1BB bispecific antibody) as monotherapy for patients with advanced extrapulmonary neuroendocrine carcinoma ("**EP-NEC**") has been selected as a Late-Breaking Abstract ("**LBA**") and accepted for a Proffered Paper presentation at the 2026 Annual Meeting of the European Society for Medical Oncology ("**2026 ESMO**"). The selection reflects the innovative nature and significant clinical value of the study, and the findings hold the potential to transform current clinical practice and reshape the standard-of-care landscape for advanced EP-NEC. Notably, three studies of the Company have been selected for Proffered Paper presentations at 2026 ESMO, placing the Company among the leading Chinese biopharmaceutical companies by number of such presentations.

Details of the study selected as an LBA are set out below.

Study Title: Opamtistomig (LBL-024) monotherapy in advanced extra-pulmonary neuroendocrine carcinoma (EP-NEC) after >2 prior lines of therapies: results from a pivotal, registrational phase IIb study of a novel PD-L1x4-1BB bispecific antibody

Presentation Type: Proffered Paper Presentation

Principal Investigator: Professor Shen Lin (沈琳), Peking University Cancer Hospital (北京大學腫瘤醫院)

Presenter: Dr. Lu Ming (陸明), Peking University Cancer Hospital (北京大學腫瘤醫院)

Presentation Time: 10:15–10:25, local time, October 26

The pivotal Phase IIb study selected as an LBA at ESMO is designed to evaluate the efficacy and safety of LBL-024 monotherapy in patients with advanced EP-NEC who have received at least two prior lines of systemic therapy. Data from the study provided core support for the Company's submission of a New Drug Application ("**NDA**") to the relevant regulatory authority.

The Company has secured three Proffered Paper presentations at 2026 ESMO, comprising: (i) the pivotal registrational Phase IIb study of LBL-024 monotherapy for advanced EP-NEC, which has also been selected as an LBA; (ii) the Phase Ib/II study of LBL-024 in combination with chemotherapy as a first-line treatment for EP-NEC; and (iii) the Phase I study of LBL-034 for the treatment of relapsed or refractory multiple myeloma ("**RRMM**").

Proffered Paper presentations are among the highest-profile oral presentation categories at the ESMO and are reserved for original research data of exceptional quality. They represent recognition by the international oncology community of a study's innovation, data quality and clinical value. The selection of three studies of the Company for Proffered Paper presentations at the 2026 ESMO represents not only a breakthrough for the individual studies, but also broad recognition of the Company's innovation capabilities, clinical development system and multi-tumor portfolio, demonstrating its ability to consistently produce high-quality clinical research and compete on the international academic stage.

In addition, four other high-quality studies of the Company have been selected for poster presentation, covering a clinical study of LBL-024 in biliary tract cancer ("**BTC**"), a mechanistic study in microsatellite-stable colorectal cancer and several meta-analyses. Spanning solid-tumor clinical exploration and systematic review of research data, these studies demonstrate the breadth, precision and diversity of the Company's research and development portfolio.

ABOUT EP-NEC

Neuroendocrine carcinoma ("**NEC**") is a highly malignant immunologically "cold" tumor, accounting for approximately 10% to 20% of neuroendocrine neoplasms. NEC may arise in various organs, including the lung, gastrointestinal tract and bladder. NEC can be classified into pulmonary NEC and extrapulmonary NEC. EP-NEC shares the highly aggressive and metastatic characteristics of small cell lung cancer ("**SCLC**"), progresses rapidly, and most patients with NEC present with advanced-stage disease or distant metastases at diagnosis. Systemic treatment options for NEC are limited, with suboptimal efficacy and poor prognosis.

There are currently no therapies specifically approved by regulatory authorities worldwide for EP-NEC. First-line treatment for advanced EP-NEC primarily consists of platinum-based chemotherapy, with an objective response rate ("**ORR**") of approximately 30% to 50% and a median overall survival ("**mOS**") of only around one year. There is no standard treatment following progression on first-line therapy. Second-line treatment options may include oxaliplatin-based FOLFOX, irinotecan-based FOLFIRI, CAPTEM with or without bevacizumab, or temozolomide monotherapy. However, the efficacy of these treatment options remains limited, with an ORR of approximately 10% to 25% and an mOS of approximately eight months. Accordingly, there remains a substantial unmet medical need for patients with advanced EP-NEC, underscoring the urgent need for new and effective treatment options.

ABOUT LBL-024 (OPAMTISTOMIG)

LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB, with the potential to become a pan-tumor IO 2.0 cornerstone therapy that offers survival benefits. To date, LBL-024 has been evaluated in clinical studies for 14 indications, including one pivotal single-arm registrational clinical study, one confirmatory Phase III clinical study and nine proof-of-concept studies, covering multiple major cancer types and "cold tumors." Among the seven tumor types in which LBL-024 has been clinically validated, LBL-024 has demonstrated outstanding clinical value and broad therapeutic prospects, including extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC) and ovarian cancer (OC).

Leveraging our self-developed X-body™ platform with full intellectual property rights, LBL 024 achieves conditional activation of 4-1BB, relieving PD-1/PD-L1 immunosuppression while enhancing 4-1BB regulated T-cell activation, achieving a synergistic effect in eliminating tumors. LBL-024 demonstrates a safety profile comparable to PD-1/PD-L1 inhibitors and greater potential for broad-spectrum cancer treatment. In particular, activation of 4-1BB can reactivate the exhausted T cells and substantially promote their proliferation, making 4-1BB-targeted therapies potentially suitable for the treatment of immunologically "cold tumors" that are resistant or unresponsive to PD-1/PD-L1 inhibitors, and may bring long-lasting survival benefits.

In October 2024, LBL-024 was granted Breakthrough Therapy Designation by the NMPA, and in November 2024, it received Orphan Drug Designation from the U.S. Food and Drug Administration (the "**FDA**"). In January 2026, LBL-024 was granted Fast Track Designation by the FDA and Orphan Drug Designation in the European Union. In July 2026, the Marketing Authorization Application of LBL-024 as an innovative biological product was included in the NMPA's priority review and approval procedure and was formally accepted in August 2026. LBL-024 is expected to become the world's first approved 4-1BB antibody drug, the world's first approved agonistic antibody drug and the world's first approved therapy targeting EP-NEC.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-024, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, September 21, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.